TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Research Report·October 31, 2026

Ascendis Pharma (ASND): Rare-Disease Growth Is Accelerating

Ascendis Pharma is transitioning into a commercial rare-disease platform, with Q2 2026 product revenue up 105% year over year and YORVIPATH emerging as the main growth engine. Valuation and execution risks remain, but the company’s expanding portfolio and strong launch momentum support a Buy view.

Research ReportASNDHealthcareBiotechnologyBiotech
By TickerSpark·October 31, 2026·16 min read

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Ascendis Pharma (ASND): Rare-Disease Growth Is Accelerating
B
Overall
B-
Balance Sheet
B+
Income
B+
Estimates
B-
Valuation
TickerSpark AI RatingBuy
▌Investment Summary
Ascendis Pharma (ASND) is a Buy and is earning an overall grade of B, supported by rapid commercial growth, a broadening rare-disease portfolio, and improving operating leverage. Our fair value is $280, reflecting the company’s transition from development-stage biotech to a scaled commercial platform while still accounting for valuation and execution risk.

Thesis

Ascendis Pharma (ASND) has moved from a development-stage biotech toward a commercial rare-disease company. Q2 2026 product revenue reached €315 million, up 105% year over year, led by YORVIPATH at €252 million, SKYTROFA at €55 million, and the new YUVIWEL launch at €8 million.

The investment case rests on three facts: revenue is scaling rapidly, YORVIPATH is becoming the commercial engine, and Ascendis is building a portfolio around its TransCon platform rather than relying on a single clinical asset. Management also reported more than €500 million of expected 2026 operating cash flow and a goal of €5 billion in revenue by 2030.

The main restraint is valuation and execution risk. The stock trades near $253.00, at 19.4x trailing earnings, 21.1x forward earnings, and 13.8x enterprise value to revenue. Those multiples can be supported by the 114.7% reported revenue growth rate, but the 3-for-7 earnings beat record, negative 2025 equity, product concentration, and YUVIWEL intellectual-property dispute argue for a measured Buy rather than an aggressive rating.

Company Overview

Ascendis Pharma A/S is a Denmark-based biopharmaceutical company listed on Nasdaq under ASND. Founded in 2006, the company had 1,189 employees and focuses on TransCon-based therapies for rare endocrine and growth disorders, with additional programs in oncology and partnered therapeutic areas.

The commercial portfolio consists of SKYTROFA for pediatric and adult growth hormone deficiency, YORVIPATH for adults with chronic hypoparathyroidism, and YUVIWEL for pediatric achondroplasia. All three products use the TransCon platform to extend drug exposure and reduce dosing burden.

Ascendis generated $691.7 million of revenue in 2025, compared with $363.6 million in 2024 and $266.7 million in 2023. The latest quarterly series shows revenue of $344.9 million for the quarter ended June 30, 2026, following $250.7 million in the first quarter.

▌Common Questions

Frequently asked questions

+Is ASND stock a buy right now?
Yes. Ascendis Pharma is a Buy because revenue is scaling quickly, YORVIPATH is becoming a meaningful commercial engine, and the company is building a multi-product rare-disease franchise rather than relying on a single asset.
+What is ASND's fair value?
Ascendis Pharma's fair value is $280. That view reflects the report’s valuation framework, which weighs the stock’s 19.4x trailing earnings, 21.1x forward earnings, and 13.8x EV/revenue against 114.7% reported revenue growth, strong YORVIPATH momentum, and the execution risk tied to product concentration and the YUVIWEL IP dispute.
+
▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

Business Segment Deep Dive

Ascendis reports its business primarily through commercial products rather than traditional operating segments. YORVIPATH is the largest revenue contributor, with Q2 2026 revenue of €252.1 million compared with €103.0 million in the prior-year quarter. Its growth is shifting the company toward a higher-scale commercial model.

SKYTROFA generated €55.2 million in Q2 2026, compared with €50.7 million a year earlier. The product has surpassed 20,000 unique enrollments globally and remains the leading long-acting growth hormone by U.S. brand value according to management.

YUVIWEL contributed €7.6 million in its first commercial quarter. More than 220 U.S. patients had enrolled by July 31, 2026, more than 100 healthcare providers were prescribing it, and more than 65% of enrollments had reimbursement approval. That early launch gives Ascendis a third commercial growth vector, although its revenue base remains much smaller than YORVIPATH.

Get AI research on any stock

Instant reports, daily intelligence, and an AI analyst in your pocket.

Get Started →

Flagship Product Analysis

YORVIPATH is the flagship product because it addresses the underlying hormone deficiency in chronic hypoparathyroidism by replacing parathyroid hormone throughout the body. Management cited more than 800,000 patients living with hypoparathyroidism across the geographic regions covered by Ascendis' commercial infrastructure.

Long-term Phase II and Phase III data showed an 82% to 86% sustained response rate on a multicomponent endpoint, with reported clinical benefit across the central nervous system, kidney, small intestine, and bone. Patient retention reached as high as 95% after five years of treatment.

The commercial evidence is also strong. YORVIPATH was available commercially or through named-patient programs in more than 35 countries, and Q2 revenue reached €252 million. The combination of broad access, chronic treatment duration, and reported retention gives YORVIPATH the clearest path to supporting operating leverage.

Innovation & Competitive Advantage

TransCon is the strategic center of Ascendis. The platform combines a known active molecule with a prodrug and sustained-release design, allowing the company to pursue longer-acting therapies without discovering an entirely new biological pathway for every program. The three commercial products demonstrate that the platform has produced marketed medicines, not only laboratory concepts.

The platform also supports combination development. In the COACH trial, the combination of TransCon CNP and TransCon Growth Hormone produced sustained annualized growth velocity and improved body proportionality through week 78, with all 21 enrolled children remaining on therapy at that point. Ascendis plans to begin a Phase III combination trial in children with achondroplasia.

Ascendis also has partnered optionality. Novo Nordisk (NVO) is advancing a once-monthly TransCon semaglutide program, while Eyconis has initiated a first-in-human study of a TransCon anti-VEGF treatment for wet age-related macular degeneration. These programs extend the platform beyond the current endocrine franchise.

Operations & Supply Chain

The commercial organization has already demonstrated broad launch execution. YORVIPATH reached more than 35 countries through commercial sales or named-patient programs, while SKYTROFA surpassed 20,000 global enrollments. YUVIWEL reached more than 220 U.S. enrollments within its first months, showing that Ascendis can support multiple launches at once.

Management spent €76 million on research and development in Q2 2026, up from €59 million in Q1, and €173 million on selling, general, and administrative expenses, up from €145 million. The spending increase reflects continued investment in the pipeline, YORVIPATH commercialization, and the YUVIWEL launch.

Ascendis' 2025 annual report identifies reliance on third-party manufacturers and single-source suppliers for some parent drugs and other components. That structure limits fixed manufacturing investment but makes quality, capacity, and supplier continuity important operating variables as product volume expands.

Market Analysis

Ascendis operates in rare endocrine markets where dosing convenience and treatment access can matter as much as molecule novelty. Chronic hypoparathyroidism, growth hormone deficiency, and achondroplasia each have specialist prescriber bases and substantial unmet needs, creating room for differentiated products with durable clinical benefits.

A 2026 market estimate placed the global biotechnology industry at $2.4 trillion, with a projection of $4.9 trillion by 2032. The broad figure is less useful than the product-level evidence for ASND, where YORVIPATH already produced €252 million in one quarter and YUVIWEL is expanding into a new commercial category.

The industry is moving toward longer-acting biologics, personalized treatment, and advanced delivery systems. TransCon fits the longer-acting trend directly, while the company's once-weekly products address adherence and caregiver burden in chronic pediatric and adult diseases.

Like what you're reading?

Get full access to AI-powered research reports, market analysis, and portfolio tools.

Get Started →

Customer Profile

The primary customers are patients with chronic rare endocrine disorders, specialist physicians, hospitals, specialty pharmacies, and commercial or government payers. YORVIPATH serves adults with chronic hypoparathyroidism, SKYTROFA serves pediatric and adult growth hormone deficiency, and YUVIWEL serves children with achondroplasia.

The product profile places a premium on persistence and ease of use. YORVIPATH's reported five-year retention of as high as 95% and SKYTROFA's more than 20,000 unique enrollments provide evidence that patients and providers have accepted the convenience proposition at scale.

YUVIWEL's early customer data are encouraging but still young. Nearly 80% of U.S. centers of excellence had prescribed YUVIWEL within its first four months, while more than 65% of U.S. enrollments had reimbursement approval by July 31, 2026. Those figures connect prescriber adoption with payer access, two requirements for a durable launch.

Competitive Landscape

In hypoparathyroidism, Ascendis faces competition from AstraZeneca (AZN) and Amolyt Pharma's eneboparatide program, MBX Biosciences' canvuparatide program, and the historical presence of Takeda's (TAK) Natpara. YORVIPATH's advantage is its status as an approved replacement therapy with global commercial reach.

In achondroplasia, BioMarin (BMRN) is the key commercial rival through VOXZOGO. BridgeBio (BBIO) and QED Therapeutics also sit within the competitive field, while Ascendis is positioning YUVIWEL around a differentiated clinical profile and additional combination opportunities with TransCon Growth Hormone.

SKYTROFA competes with long-acting and conventional growth hormone products from Pfizer (PFE), Novo Nordisk (NVO), Eli Lilly (LLY), Roche (RHHBY), and other established manufacturers. Ascendis' more than 20,000 enrollments and stated U.S. leadership by long-acting growth hormone brand value indicate meaningful commercial traction, although the category remains competitive.

Macro & Geopolitical Landscape

Biotechnology funding conditions improved in the cited 2026 industry data. Biotech market capitalization rose 28.8% to $1.65 trillion, while total capital raised increased 26%. That backdrop supports financing and partnership activity, although ASND's growing operating cash flow reduces its immediate dependence on external capital.

Pricing and reimbursement remain structural risks. Industry estimates place more than $300 billion of pharmaceutical sales at risk from patent expirations through 2030, while policy research highlights pricing pressure, access changes, tariffs, and onshoring requirements. Ascendis' rare-disease focus can support premium pricing, but reimbursement approval remains central to product uptake.

The YUVIWEL legal dispute with BioMarin adds a company-specific geopolitical and regulatory layer. Ascendis said the relevant patent had been invalidated in Europe and described a U.S. International Trade Commission process involving an initial opinion, an ITC decision, and a potential presidential order. Management stated that the dispute would not materially change the company's path toward its €5 billion 2030 revenue objective.

Balance Sheet Health

▌Premium Members Only

Negative 2025 equity and a 3-for-7 earnings beat record temper the balance sheet story even as management points to more than €500 million of expected 2026 operating cash flow.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Income Statement Strength

▌Premium Members Only

Q2 2026 product revenue surged to €315 million, up 105% year over year, with YORVIPATH alone contributing €252 million of the total.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Estimates Outlook

▌Premium Members Only

Management is guiding to more than €500 million of expected 2026 operating cash flow and €5 billion in revenue by 2030, signaling a steep growth runway.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Valuation Assessment

▌Premium Members Only

At about $253 per share, ASND trades at 19.4x trailing earnings, 21.1x forward earnings, and 13.8x EV/revenue, leaving room for upside but not a bargain.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Target Prices & Recommendation

▌Premium Members Only

The report’s valuation framework places fair value at $280, with the stock’s current price near $253 implying modest upside from here.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Closing

Ascendis Pharma has the ingredients of a durable commercial biotech: three approved products, a proprietary delivery platform, strong product-level growth, and improving cash generation. YORVIPATH is already carrying the business, while SKYTROFA provides an established base and YUVIWEL creates a new launch opportunity in achondroplasia.

The stock is investable at the current quoted price, but it is not a bargain disguised as a biotech. The Buy rating depends on execution across launches, reimbursement, manufacturing, and pipeline development. For a medium-term investor, the strongest risk-reward improves below $235, while prices above $325 would demand more certainty than the present earnings record provides.

Why is Ascendis Pharma growing so fast?
Growth is being driven primarily by YORVIPATH, which generated €252.1 million in Q2 2026 versus €103.0 million a year earlier. SKYTROFA added €55.2 million and YUVIWEL contributed €7.6 million in its first commercial quarter, giving the company three revenue streams.
+What are the biggest risks for ASND investors?
The biggest risks are valuation, execution, and product concentration. The stock already trades at 19.4x trailing earnings and 21.1x forward earnings, while the report also flags a 3-for-7 earnings beat record, negative 2025 equity, and an intellectual-property dispute around YUVIWEL.
+How important is YORVIPATH to the investment case?
YORVIPATH is the flagship product and the clearest driver of operating leverage. It delivered €252 million in Q2 2026 revenue, is available in more than 35 countries, and has long-term data showing an 82% to 86% sustained response rate with patient retention as high as 95% after five years.
▌For Active Investors

Want Reports Like This on Any Stock?

Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.

Get Full Access →

Not ready to subscribe? ·

▌For Active Investors

Stock research for every investor

  • Reports on any stock
  • Daily market intelligence
  • AI analyst in your pocket
  • Portfolio analysis tools
Get Full Access →

Cancel anytime

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌More on ASND

More to read

All articles
Ascendis Pharma A/S (ASND) nosedives 59.8% after-hours
ASND

Ascendis Pharma A/S (ASND) nosedives 59.8% after-hours

Ascendis Pharma A/S (ASND) nosedives in after-hours trading after a delayed market reassessment of its Novo Nordisk rights reversion, ASBMR data, and funding needs. The sharp move reflects rising execution risk even as analysts still see upside in the company’s TransCon platform and pipeline.

Oct 15·5 min
Ascendis Pharma (ASND): YORVIPATH Drives Commercial Scale
ASND

Ascendis Pharma (ASND): YORVIPATH Drives Commercial Scale

Ascendis Pharma is transitioning into a scaled commercial biopharma, led by rapid YORVIPATH growth and a promising YUVIWEL launch. The stock still screens expensive, so the report lands on Hold despite strong revenue momentum.

Sep 15·20 min
Ascendis Pharma A/S (ASND) falls 13% on strategic reset
ASND

Ascendis Pharma A/S (ASND) falls 13% on strategic reset

Ascendis Pharma A/S (ASND) falls sharply after a strategic reset that includes returned obesity rights, a $400 million buyback, and a Raymond James downgrade. Strong revenue growth and a solid cash position support the business, but investors are weighing higher execution risk in metabolic programs.

Sep 15·5 min